Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > CMPS VS MMED and Share Price.. This is where we are heading

<< Previous

Bullboard Posts

Next >>

Comment by MrVerbatim9800on Apr 28, 2021 10:45am

331 Views

Post# 33082032

RE:RE:CMPS VS MMED and Share Price.. This is where we are heading

We will just have to wait and see :)

TeddyTenBags wrote: Sounds like you don't understand how stocks work. MindMed's valuation is higher than CMPS ($1.4B vs. $1.3B), but Compass has a higher share price because they have significantly less outstanding shares.

Get an education.

MrVerbatim9800 wrote: The two companies are virtually identical. Same space, same stage of development same revenue potential, very similar scope and vision.

CMPS is currently evaluated at $70.00 USD and currently trading around $36.00 USD.

This is where MMED is heading very soon. Just keep that in mind ;) SHRM has some catching up to do and some bridges to rebuild but, remember, it has been generating revenue the entire time it was halted. I'm looking forward to their next NR which will probaly include financials.

These prices are nothing compared to where we will be at when this sector really opens up. With all of the positive attention being focused on this space lately, expect the "boom" sooner rather than later.

V